These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 12037506)

  • 41. The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.
    Yee MS; Pavitt DV; Dhanjil S; Godsland IF; Richmond W; Johnston DG
    Diabet Med; 2010 Dec; 27(12):1392-400. PubMed ID: 21059092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Precautions for use and contraindications of thiazolidinediones. A cardiologist opinion].
    Cohen-Solal A
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S51-5. PubMed ID: 12037510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
    Nass CM; Blumenthal RS
    Am J Manag Care; 2000 Dec; 6(24 Suppl):S1247-56; quiz S1257-8. PubMed ID: 11142005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anticipated US approval for rosiglitazone and pioglitazone.
    Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
    [No Abstract]   [Full Text] [Related]  

  • 48. Insulin sensitizers.
    Zangeneh F; Kudva YC; Basu A
    Mayo Clin Proc; 2003 Apr; 78(4):471-9. PubMed ID: 12683699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glitazones: clinical effects and molecular mechanisms.
    Stumvoll M; Häring HU
    Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
    Otsuki M; Goya K; Kasayama S
    Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rosiglitazone.
    Goldstein BJ
    Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacologic therapy for type 2 diabetes mellitus.
    DeFronzo RA
    Ann Intern Med; 2000 Jul; 133(1):73-4. PubMed ID: 10877745
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of thiazolidinediones on cardiovascular risk factors.
    Gouda BP; Asnani S; Fonseca VA
    Compr Ther; 2002; 28(4):200-6. PubMed ID: 12506489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Thiazolidinediones: effect of the pioglitazone on hyperglycemia, dyslipidemia and cardiovascular risk].
    Tan MH
    Rev Clin Esp; 2003 Jan; 203(1):33-40. PubMed ID: 12605799
    [No Abstract]   [Full Text] [Related]  

  • 56. Addressing the insulin resistance syndrome: a role for the thiazolidinediones.
    Zimmet P
    Trends Cardiovasc Med; 2002 Nov; 12(8):354-62. PubMed ID: 12536122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Tuepker J
    Circulation; 2003 Apr; 107(16):e109; author reply e109. PubMed ID: 12719295
    [No Abstract]   [Full Text] [Related]  

  • 58. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.
    Honisett SY; Stojanovska L; Sudhir K; Kingwell BA; Dawood T; Komesaroff PA
    Diabetes Care; 2003 Nov; 26(11):3194-5. PubMed ID: 14578270
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes.
    Pan HJ; Reifsnyder P; Vance DE; Xiao Q; Leiter EH
    Diabetes; 2005 Jun; 54(6):1854-62. PubMed ID: 15919809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Rosiglitazone: a clinical development focused on cardio-vascular prevention].
    Valensi P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S35-40. PubMed ID: 12037506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.